{"id":33323,"date":"2012-11-29T11:32:25","date_gmt":"2012-11-29T16:32:25","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=33323"},"modified":"2012-11-29T11:52:54","modified_gmt":"2012-11-29T16:52:54","slug":"following-earlier-recall-ranbaxy-halts-manufacturing-atorvastatin","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/11\/29\/following-earlier-recall-ranbaxy-halts-manufacturing-atorvastatin\/","title":{"rendered":"Following Earlier Recall, Ranbaxy Halts Manufacturing of Atorvastatin"},"content":{"rendered":"<p>Ranbaxy, the often-troubled manufacturer of generic drugs, will temporarily stop manufacturing generic atorvastatin. On November 9, 2012, the company announced a voluntary recall of some lots of atorvastatin because of possible contamination with glass particles. An FDA <a href=\"http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm329951.htm\">statement<\/a>\u00a0today said that Ranbaxy will discontinue making the drug &#8220;until it has thoroughly investigated the cause of the glass particulates and remedied the problem.&#8221;<\/p>\n<p>To date, no reports of harm from the contamination have been received by the FDA. Both FDA and Ranbaxy believe there is only a low likelihood that there will be adverse events related to the problem.<\/p>\n<p>The FDA said it does not anticipate a shortage of atorvastatin because of the recall, but that it &#8220;is working with other manufacturers of atorvastatin to ensure adequate market supply.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ranbaxy, the often-troubled manufacturer of generic drugs, will temporarily stop manufacturing generic atorvastatin. On November 9, 2012, the company announced a voluntary recall of some lots of atorvastatin because of possible contamination with glass particles. An FDA statement\u00a0today said that Ranbaxy will discontinue making the drug &#8220;until it has thoroughly investigated the cause of the [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[585,210,196,223,1578,584],"class_list":["post-33323","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-atorvastatin","tag-cholesterol","tag-fda","tag-generics","tag-ranbaxy","tag-statins"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=33323"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/33323\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=33323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=33323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=33323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}